https://www.pharmaradar360.com/article/30fed1b03cacf439PharmaRadar360en2026-04-06T06:30:00.000Z大阪大学免疫学フロンティア研究センターとの共同研究による免疫性血小板減少症に関する研究成果がBlood誌に掲載https://www.pharmaradar360.com/article/30de1058add9bb79PharmaRadar360en2026-04-06T06:30:00.000ZResearch Results on Immune Thrombocytopenia from a Joint Study with Osaka University’s IFReC Published in Bloodhttps://www.pharmaradar360.com/article/4bdde72027b7c6d4PharmaRadar360en2026-04-06T03:00:00.000Z[SHINSA]List of Approved Drugs: April 2004 to September 2025https://www.pharmaradar360.com/article/d751e33aa5c6e59dPharmaRadar360en2026-04-06T03:00:00.000Z[SHINSA]Software as a Medical Device (SaMD) page updatedhttps://www.pharmaradar360.com/article/c6b1bc43b22858d6PharmaRadar360en2026-04-06T00:00:00.000ZPharma Research & Developmenthttps://www.pharmaradar360.com/article/0895c1e9fecacc34PharmaRadar360en2026-04-06T00:00:00.000ZIR and Shareholder Contactshttps://www.pharmaradar360.com/article/b78a2ac9734a36b8PharmaRadar360en2026-04-06T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/7b0a5c2670715840PharmaRadar360en2026-04-06T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/385db0a54dababe5PharmaRadar360en2026-04-06T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/832f3b3887ffde11PharmaRadar360en2026-04-06T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/3b9fcb540bd09324PharmaRadar360en2026-04-06T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/fc42954948a76d40PharmaRadar360en2026-04-06T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/8e00537609db47c9PharmaRadar360en2026-04-06T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/cac0130b1a4d7be0PharmaRadar360en2026-04-06T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/d7dc927002a017bfPharmaRadar360en2026-04-06T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/be9f17fc8a6d684dPharmaRadar360en2026-04-06T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/e0c28c2be852c373PharmaRadar360en2026-04-06T00:00:00.000Znews releases enhttps://www.pharmaradar360.com/article/bde28323945e285fPharmaRadar360en2026-04-06T00:00:00.000ZIDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer